Seeking Alpha |
August 19th, 2008 |
Email this
Ads for flu vaccines have traditionally been confined to public service announcements (PSAs), health and media alerts. So, that's why I was surprised to see this colorful full-page ad in The New York Times last weekend for FluMist from AstraZeneca (AZN)/MedImmune.[...]
AstraZeneca has signed a memorandum of understanding with the National Cancer Centre Singapore and the National University Hospital to develop anti-cancer compounds.[...]
Abbott and AstraZeneca have signed an agreement pursuant to which, Abbott will promote AstraZeneca's Crestor, a medication used along with diet to reduce high cholesterol.[...]
In 2006, we posted about striking allegations that guidelines used in the state of Texas and elsewhere for management of adult psychiatric patients, the Texas Medication Algorithm Project, (TMAP) were influenced by payments by pharmaceutical companies to the state, and to the people developing the guidelines.Now the Dallas Morning News [...]
pharmalot |
August 18th, 2008 |
Email this
Company 2007 2012 Percent Change Schering-Plough 0.38 1.58 315.8% Amgen 4.50 1.46 -67.6% Bristol-Myers Squibb 1.08 0.84 -21.7% Wyeth 0.60 0.49 -18.2% Abbott Labs 1.73 0.42 75.7% Johnson & Johnson 0.39 0.38 -2.4% GlaxoSmithKline 0.27 0.32 17.3% Eli Lilly 6.64 0.29 -95.6% Novartis 2.27 0.27 -88.2% Merck 0.51 0.26 -49.0% [...]
pharmalot |
August 18th, 2008 |
Email this
A state mental health plan naming the preferred psychiatric drugs for children has been quietly put on hold over fears drugmakers may have given researchers consulting contracts, speakers fees or other perks to help get their products on the list, The Dallas Morning News reports. The Children's Medication Algorithm Project, [...]
FierceBiotech |
August 15th, 2008 |
Email this
It may be an early-stage study, but Micromet's antibody drug blinatumomab is showing promise for non-Hodgkin's lymphoma patients. In a Phase I study, all seven participants responded to the drug, demonstrating tumor regression and in some cases, complete remission. "We observed tumor regression in patients at serum levels of blinatumomab, which [...]
FierceBiotech |
August 15th, 2008 |
Email this
AstraZeneca has forged a new partnership with the National Cancer Centre Singapore and the National University Hospital to develop anti-cancer compounds. The deal covers both clinical and pre-clinical development of therapies for inoperable Hepatocellular Carcinoma, a liver cancer. In a statement, AstraZeneca said the partnership would further its drug development activities in Asia. [...]
Abbott and AstraZeneca have entered into an agreement for Abbott to promote AZ's cholesterol drug Crestor. Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote the drug alongside AZ in the U.S., excluding Puerto Rico. Financial terms were not disclosed. This agreement is the [...]
OnPharma |
August 8th, 2008 |
Email this
As AstraZeneca and Baxter have discovered, knowledge management technologies can harness a company’s collective (and global) intellect[...]
> The FDA has approved Cleviprex--an intravenous blood pressure drug--from The Medicines Company. Story > Expression Genetics has completed its $12-million Series B financing. The final, $7 million portion of the financing was secured in July. The money will be used to fund the clinical development of its lead product--the [...]
Sales up 9% despite challenging conditions in the US [Published: 01st August 2008][...]
Handa Pharmaceuticals has confirmed that its abbreviated new drug application for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca's Seroquel XR, has been accepted for filing by the FDA.[...]
AstraZeneca 2Q08 2Q Revenues: $8.0 billion (+9%, +2% at Constant Exchange Rate) 2Q Earnings: $1.6 billion (+13%, +6% CER) YTD Revenues: $15.6 billion (+10%, +3% CER) YTD Earnings: $3.1 billion (+4%, -3% CER) Comments: Sales were buoyed by 35%/27% growth in Crestor, which reached $916 million in 2Q08. Toprol sales [...]
AstraZeneca, the Anglo-Swedish pharmaceutical company, has lifted its earnings per share guidance after second-quarter results beat expectations[...]
medgadget |
August 3rd, 2008 |
Email this
Apple's website features AstraZeneca's Heart FXPod, a "53-foot-long mobile van outfitted with five virtual reality stations that offer a complex multimedia demonstration involving custom devices and interactive feedback." So far, the van has logged over 70,000 miles in the field, traveling to medical centers and physician's conferences. Each of the [...]
Minimum Requirements -Major in Biological Sciences preferred -At least one year of undergraduate work towards a Bachelor of Sciences, more than one year undergraduate [...]
* Ph.D. degree in Microbiology or Molecular Biology, and at least 2 years of post-doctoral experience * Expertise in genetic manipulation of pathogenic bacterial systems * Familiarity with standard bioinformatics [...]
Date Posted: 03-03-2008 Functional Area: Sales State: New York City: New York City Territory: Forest Hills NY 6 Other States: N/A Field/Home based position: Yes Search Band: Band[...]
Job Summary External Summary of Primary Responsibilities: Provides inspirational leadership and strategic direction to PSSs in order to achieve performance objectives; this is[...]
